ACON
HEALTHCAREAclarion Inc
What's Moving ACON Today?
No stock-specific AI insight has been generated for ACON yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.89
Fundamentals
Trading
ACON News
22 articles- Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClubYahoo Finance Singapore·Jun 10, 2026
- Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan PlatformYahoo Finance·Jun 9, 2026
- Aclarion enlists PRIA in push for insurer coverage of AI back-pain scansStock Titan·Jun 9, 2026
- Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition ProposalYahoo Finance·Jun 8, 2026
- Aclarion Stockholders Approve All Proposals at 2026 Annual MeetingYahoo Finance·Jun 8, 2026
- Aclarion (ACON) shareholders elect board, ratify auditor and approve equity planStock Titan·Jun 4, 2026
- Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence GenerationYahoo Finance·Jun 3, 2026
- Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker StudyYahoo Finance·Jun 1, 2026
- Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited ProposalYahoo Finance·May 28, 2026
- Echo Lake Capital Offers To Acquire Aclarion Inc.Yahoo Finance·May 28, 2026
- Aclarion (ACON) Upgraded to Buy: Here's WhyYahoo Finance·May 19, 2026
- Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 13, 2026
- Natera (NTRA) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate EnrollmentYahoo Finance·May 7, 2026
- Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.Yahoo Finance·May 6, 2026
- Aclarion Announces Second Commercial Agreement with Weill Cornell MedicineYahoo Finance·May 5, 2026
- Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical AdoptionYahoo Finance·Apr 30, 2026
- Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of NociscanGlobeNewswire Inc.·Apr 28, 2026
- Aclarion Announces $2.5 Million Stock Repurchase PlanYahoo Finance·Apr 22, 2026
- Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back PainYahoo Finance·Apr 16, 2026
- Aclarion Receives Pinnacle Award for AI InnovationYahoo Finance·Apr 14, 2026
- Aclarion Announces Agreement with Weill Cornell MedicineYahoo Finance·Apr 8, 2026
All 22 articles loaded
Price Data
52-Week Range
$2.89
Fundamentals
Trading
About Aclarion Inc
Aclarion Inc (ACON) is an innovative healthcare technology company focused on developing non-invasive diagnostic solutions for musculoskeletal conditions through advanced imaging and data analytics. By leveraging machine learning, Aclarion equips healthcare professionals with actionable insights that enhance clinical outcomes and streamline treatment pathways, ultimately reducing costs. As a leader in the digital health transformation, Aclarion is uniquely positioned to address the growing demand for effective diagnostics, contributing significantly to improved patient management and care standards in an evolving healthcare environment. This strategic focus on enhancing patient care and outcomes solidifies Aclarion’s role as a key player in the future of healthcare delivery.